查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球絕經期潮熱市場 - 2023-2030年
市場調查報告書
商品編碼
1290439

全球絕經期潮熱市場 - 2023-2030年

Global Menopausal Hot Flashes Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概況

全球絕經期潮熱市場規模在2022年達到135億美元，預計到2030年將見證有利可圖的成長，達到205億美元。全球絕經期潮熱市場在2023-2030年預測期間的複合年成長率為5.5%。

絕經期潮熱市場的驅動因素包括：絕經期潮熱的發病率越來越高，絕經期潮熱的發病率越來越高，老齡化人口越來越多，對更年期及其相關症狀的認知和了解越來越多，對女性健康的關注越來越多，治療方案的進步，以及生活方式和偏好的改變。

更年期潮熱市場存在許多阻礙因素和挑戰，包括治療效果有限，更年期潮熱藥物的副作用，治療費用高，等等。

市場動態

絕經期潮熱的發病率越來越高

絕經期潮熱發病率的增加是在預測期內推動市場佔有率的主要因素。由於女性人口老齡化、預期壽命延長、吸煙、飲酒和垃圾食品等生活方式的改變、荷爾蒙變化、認知和尋求治療，以及在這一人生階段對有效管理方案的需求和對女性的支持，更年期潮熱的流行率正在增加。

潮熱的流行程度可能因人而異，有些人比其他人更頻繁、更強烈地經歷潮熱。醫療保健提供者和製藥公司正在不斷努力開發和改進治療方案，以減輕潮熱的影響，提高經歷這種常見的更年期症狀的婦女的生活品質。

絕經期潮熱藥物的副作用

與絕經期潮熱藥物相關的副作用是阻礙市場佔有率的一個主要因素。更年期潮熱藥物，包括荷爾蒙和非荷爾蒙藥物，都可能有潛在的副作用。值得注意的是，並非所有的人都會出現這些副作用，而且副作用的嚴重程度和頻率也會有所不同。

COVID-19影響分析

COVID-19大流行對醫療保健的各個方面都產生了重大影響，包括對更年期潮熱的管理和治療。在大流行期間，醫療保健系統面臨著巨大的挑戰，包括醫院不堪重負，人員短缺，以及需要將資源轉用於COVID-19的應對。非緊急和選擇性的醫療保健就診，包括與更年期症狀管理有關的就診，在一些情況下被推遲或取消，促使診斷和治療的延誤。

COVID-19大流行病對全世界的個人產生了重大的心理影響。這場大流行造成的壓力、焦慮和情緒困擾會加劇更年期症狀，包括潮熱。婦女可能需要額外的支持和資源來管理大流行病對其更年期症狀的心理和情感影響。

俄羅斯-烏克蘭衝突分析

俄羅斯-烏克蘭衝突影響了該地區的更年期潮熱市場。衝突會給受影響地區的醫療基礎設施帶來壓力。醫療服務的中斷，醫療設施的損壞，以及醫護人員的流離失所都會影響醫療服務的可用性和可及性，包括更年期症狀管理。

由於戰爭期間的壓力、破壞性環境等原因，衝突直接或間接地影響了更年期潮熱市場。這可能會阻礙婦女獲得醫療保健服務，包括更年期潮熱的診斷和治療。

目錄

第一章：方法和範圍

  • 研究方法
  • 報告的研究目標和範圍

第二章：定義和概述

第三章：執行摘要

  • 按產品分類的摘要
  • 按配銷通路分類
  • 按終端用戶分類
  • 按地區分類

第四章：動態變化

  • 影響因素
    • 驅動因素
      • 更年期潮熱發病率的增加
    • 限制因素
      • 更年期潮熱藥物的副作用
    • 機會
    • 影響分析

第五章：行業分析

  • 波特五力分析
  • 供應鏈分析
  • 價格分析
  • 監管分析

第六章：COVID-19分析

  • COVID-19的分析
    • COVID-19之前的情況
    • COVID-19期間的情況
    • 後COVID-19及未來的情況
  • 在COVID-19期間的定價動態
  • 需求-供應譜系
  • 大流行期間與市場有關的政府計劃
  • 製造商的戰略計劃
  • 結語

第七章：按產品分類

  • 荷爾蒙產品
    • 雌激素
      • 普瑪林
      • 薇姿
      • 薇姿-點
    • 孕激素
      • 普羅米修姆
    • 組合產品
      • 普羅旺斯
      • 杜維
  • 非荷爾蒙產品
    • 布里斯黛爾
    • 其他產品
  • 其他產品

第8章：按配銷通路分類

  • 網路商店
  • 零售店
  • 其他

第九章：按終端用戶分類

  • 醫院
  • 專科診所
  • 學術和研究機構

第十章：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美其他地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 亞太其他地區
  • 中東和非洲

第11章：競爭格局

  • 競爭格局
  • 市場定位/佔有率分析
  • 合併和收購分析

第十二章：公司簡介

  • Bayer AG
    • 公司概述
    • 產品組合和描述
    • 財務概況
    • 主要發展情況
  • Novartis AG
  • Pfizer Inc.
  • Novo Nordisk Corporation
  • AbbVie Inc. (Allergan Plc)
  • Hisamitsu Pharmaceutical Co. Inc.
  • Ferring Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • Noven Pharmaceuticals
  • AstraZeneca

第十三章：附錄

簡介目錄
Product Code: PH1623

Market Overview

The Global Menopausal Hot Flashes Market size reached US$ 13.5 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 20.5 billion by 2030. The Global Menopausal Hot Flashes Market is exhibiting at a CAGR of 5.5% during the forecast period 2023-2030.

The menopausal hot flashes market is driven by factors such as an increasing prevalence of menopausal hot flashes, growing incidence of menopausal hot flashes, a growing aging population, increasing awareness and understanding of menopause and its associated symptoms, increasing focus on women's health, advancements in treatment options, and changing lifestyles and preferences.

There are many restraints and challenges associated with the menopausal hot flashes market, including limited treatment efficacy, side effects of menopausal hot flashes drugs, high cost of the treatment, and so on.

Market Dynamics

Increasing Prevalence of Menopausal Hot Flashes

The increasing prevalence of menopausal hot flashes is a major factor driving the market share during the forecast period. The prevalence of menopausal hot flashes is increasing due to the aging women population, longer life expectancy, lifestyle changes like smoking, alcohol consumption, and junk food, hormonal changes, awareness and seeking treatment, and the need for effective management options and support for women during this stage of life.

The prevalence of hot flashes can vary among individuals, with some experiencing them more frequently and intensely than others. Healthcare providers and pharmaceutical companies are continuously working to develop and improve treatment options to alleviate the impact of hot flashes and enhance the quality of life for women experiencing this common menopausal symptom.

Side Effects of Menopausal Hot Flashes Drugs

The side effects associated with menopausal hot flashes drugs are a major factor hindering the market share. Menopausal hot flashes drugs, including hormonal and non-hormonal medications, can have potential side effects. It is important to note that not all individuals will experience these side effects, and the severity and frequency of side effects can vary.

COVID-19 Impact Analysis

The COVID-19 pandemic has significantly impacted various aspects of healthcare, including the management and treatment of menopausal hot flashes. During the pandemic, healthcare systems have faced significant challenges, including overwhelmed hospitals, staff shortages, and the need to redirect resources to the COVID-19 response. Non-urgent and elective healthcare visits, including those related to menopausal symptom management, have been postponed or canceled in some cases, leading to delays in diagnosis and treatment.

The COVID-19 pandemic has had a significant psychological impact on individuals worldwide. Stress, anxiety, and emotional disturbances resulting from the pandemic can exacerbate menopausal symptoms, including hot flashes. Women may require additional support and resources to manage the psychological and emotional effects of the pandemic on their menopausal symptoms.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict impacted the menopausal hot flashes market in the region. The conflict can strain the healthcare infrastructure in the affected regions. Disruptions in healthcare services, damaged medical facilities, and displacement of healthcare professionals can affect the availability and accessibility of healthcare, including menopausal symptom management.

The conflict, directly and indirectly, affected the menopausal hot flashes market due to the stress, disruptive environment during the war, and so on. This may hamper the women's access to healthcare services, including diagnosis and treatment of menopausal hot flashes.

Segment Analysis

The Global Menopausal Hot Flashes Market is segmented based on product, distribution channel, end-user, and region.

Hormonal Products are Expected to Dominate the Market Share

hormonal products are expected to dominate the market share, accounting for 47.2% during the forecast period. Hormonal products, such as estrogen therapy, progesterone therapy, or combined estrogen-progestin therapy, have been widely used for many years to manage menopausal symptoms, including hot flashes. These products work by supplementing the declining estrogen levels in the body during menopause, which can help alleviate hot flashes and other associated symptoms.

Hormonal products are often considered the most effective treatment option for menopausal hot flashes, providing significant relief for many women. They are available in various formulations, including oral tablets, patches, creams, gels, and vaginal rings, offering flexibility based on individual needs.

Geographical Analysis

North America Holds the Largest Market Share during the forecast period

North America holds the largest market share of 41.5% during the forecast period due to rising demand for menopausal hot flashes treatment. North America, which includes the United States and Canada, has a significant population of women in the menopausal age range, contributing to the demand for effective management of menopausal symptoms, including hot flashes.

Competitive Landscape

The major global players in the market include: Bayer AG, Novartis AG, Pfizer Inc, Novo Nordisk Corporation, AbbVie Inc. (Allergan Plc), Hisamitsu Pharmaceutical Co. Inc., Ferring Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Noven Pharmaceuticals, and AstraZeneca.

Why Purchase the Report?

  • To visualize the Global Menopausal Hot Flashes Market segmentation based on product, distribution channel, end-user, and region and understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of menopausal hot flashes market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The Global Menopausal Hot Flashes Market Report Would Provide Approximately 54 Tables, 46 Figures And 195 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product
  • 3.2. Snippet by Distribution Channel
  • 3.3. Snippet by End-User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Prevalence of menopausal hot flashes
    • 4.1.2. Restraints
      • 4.1.2.1. Side effects of menopausal hot flashes drugs
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Post COVID-19 & Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 7.1.2. Market Attractiveness Index, By Product
  • 7.2. Hormonal Products*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 7.2.3. Estrogen
      • 7.2.3.1. Premarin
      • 7.2.3.2. Vivelle
      • 7.2.3.3. Vivelle-Dot
    • 7.2.4. Progesterone
      • 7.2.4.1. Prometrium
    • 7.2.5. Combination Products
      • 7.2.5.1. Prempro
      • 7.2.5.2. Duavee
  • 7.3. Non-Hormonal Products
      • 7.3.1.1. Brisdelle
      • 7.3.1.2. Others
  • 7.4. Others

8. By Distribution Channel

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 8.1.2. Market Attractiveness Index, By Distribution Channel
  • 8.2. Online Stores*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Retail outlets
  • 8.4. Others

9. By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Specialty Clinics
  • 9.4. Academic & Research Institutes

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Bayer AG*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Novartis AG
  • 12.3. Pfizer Inc.
  • 12.4. Novo Nordisk Corporation
  • 12.5. AbbVie Inc. (Allergan Plc)
  • 12.6. Hisamitsu Pharmaceutical Co. Inc.
  • 12.7. Ferring Pharmaceuticals
  • 12.8. Teva Pharmaceutical Industries Ltd.
  • 12.9. Noven Pharmaceuticals
  • 12.10. AstraZeneca

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us